1
关注
831
浏览

在Eudralex第4卷公布的与活性物质和剂型有关的现有欧盟GMP中,如何规定制药业的数据完整性期望(ALCOA)?

您还未登录!暂时最多只可查看 1 条回答

登录! 还没有账号?去注册

trer234 一阶会员 用户来自于: 广东省深圳市
2023-10-26 22:43

  The main regulatory expectation for data integrity is to comply with the requirement of ALCOA principles. The table below provide for each ALCOA principle the link to EU GMP references (Part I, Part II and Annex 11):

对数据完整性的主要监管期望是遵守ALCOA原则的要求。下表为每项ALCOA原则提供了与欧盟GMP参考文献(第一部分、第二部分和附件11)的链接。


关于作者

问题动态

发布时间
2023-10-26 22:43
更新时间
2023-10-26 22:43
关注人数
1 人关注

推荐内容

How should blank forms be controlled?
hy has FDA cited use of actual samples during “system suitability”?
How does FDA recommend data integrity problems be addressed?
Does each CGMP workflow on a computer system need to be validated?
When does electronic data become a CGMP record?
Should personnel be trained in preventing and detecting data integrity issues
Why is FDA concerned with the use of shared login accounts for computer systems?
What is “metadata”?
Is it acceptable to save paper printed records instead of original electronic records?
How does FDA use the term “backup” in § 211.68(b)?